Menu Search
Equities

NU Skin Enterprises Inc

NUS:DUS

NU Skin Enterprises Inc

Actions
  • Price (EUR)6.05
  • Today's Change0.25 / 4.31%
  • Shares traded44.00
  • 1 Year change-60.71%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024 07:11 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nu Skin Enterprises, Inc. is an integrated beauty and wellness company. The Company develops and distributes a comprehensive line of beauty and wellness solutions in approximately 50 markets worldwide. The Company has three brands, Nu Skin, a beauty brand; Pharmanex, a wellness brand; and ageLOC, an anti-aging brand. It develops and distributes products in two categories, beauty products and wellness products. The Company operates through seven segments: Mainland China; South Korea; Southeast Asia/Pacific, which includes Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Australia, New Zealand and other markets; Americas, which includes Canada, Latin America and the United States; Japan; Hong Kong/Taiwan, which also includes Macau; and Europe, Middle East and Africa, which includes markets in Europe, as well as Israel and South Africa. The Company’s Rhyz strategic investment arm also includes two additional segments: Manufacturing and Rhyz other.

  • Revenue in USD (TTM)1.84bn
  • Net income in USD-148.46m
  • Incorporated1996
  • Employees3.70k
  • Location
    NU Skin Enterprises IncATTN: D. MATTHEW DORNY75 WEST CENTER STPROVO 84601United StatesUSA
  • Phone+1 (801) 345-6100
  • Fax+1 (801) 345-5999
  • Websitehttps://www.nuskin.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.